Abstract:
Monitoring monoclonal antibody (mAb) levels in response to observed clinical outcomes represent reactive therapeutic drug monitoring (TDM). Conversely, proactive TDM involves regular monitoring of drug levels to anticipate and prevent potential treatment failures. By exploring the advantages and challenges associated with both approaches, this presentation will synthesize current evidence regarding the use of TDM for mAbs, and provide insights into the evolving landscape of personalized medicine in inflammatory bowel disease (IBD) management.
Dose Stratification in Chronic Inflammatory Disease Management through Pharmacogenomics: Pharmacogenomics provides valuable insights into how genetic variability influences response to therapeutic antibodies, facilitating more precise and personalized dose stratification strategies in the management of chronic inflammatory diseases
Katarina Vučićević, University of Belgrade, Serbia
Dr. Katarina Vučićević holds the position of full professor within the Department of Pharmacokinetics and Clinical Pharmacy at the Faculty of Pharmacy, University of Belgrade, Serbia. She teaches pharmacokinetics and clinical pharmacy across master’s, doctoral, and specialization studies, guiding PhD research in pharmacometrics. Her academic journey includes a Fulbright scholarship for post-doctoral training at the Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, focusing on methodological aspects of pharmacokinetic and pharmacodynamic data modeling.
With an extensive background in academia and clinical research, Katarina’s expertise lies in pharmacometric modeling and simulations. Her overarching objective is to personalize dosing regimens and enhance patient outcomes by implementing complex PKPD models as user-friendly tools in everyday clinical practice.
She served as the president of the Scientific Committee for the 8th Congress of Pharmacists of Serbia in 2022. Katarina is external expert for the evaluation of the bioequivalence studies at Medicines and Medical Devices Agency of Serbia and the Institute for Medicines and Medical Devices, Montenegro, and also a member of the Central Expert Committee for Medicines at Republic Fund of Health Insurance Serbia. She is a member of IATDMCT organization.
Currently, Katarina leads, as the principal investigator, the Bilateral Project between Serbia and France, as well as the national research optYmAb project under the PRIZMA program of the Science Fund of the Republic of Serbia. The optYmAb team, under her guidance, aims to predict factors contributing to inadequate response to monoclonal antibodies at earlier stages and propose cost-effective preventive interventions to enhance the quality of life for patients with inflammatory bowel diseases.
Marlene Santos, Polytechnic Institute of Porto, Lisbon
MARLENE SANTOS
, completed the PhD in Biomedicine in 2016, by Universidade do Porto Faculdade de Medicina, Master degree in Molecular Genetics in 2008 by Universidade do Minho and Degree in Pharmacy in 2004 by Instituto Politécnico do Porto, Escola Superior de Saúde. She is an investigator at LAQV I REQUIMTE and holds the position of Associate Professor at the School of Health, Polytechnic University of Porto, Portugal. Her research interests and expertise encompass pharmacogenomics, molecular mechanisms, and personalized medicine, particularly within the context of psychiatric, neurological and inflammatory disorders. The primary focus of her teaching activities lies in Pharmacogenomics and Neuropsychopharmacology. Actively engaged in multiple research projects related to personalized medicine, they play a key role in projects such as GENDEP09 (Genetics of Major Depressive Disorder), the CYTED project GEnoPsySEn (Development of genosensors for pharmacogenomic targets in the central nervous system), and lead WG1 in the ENOTTA COST Action (European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases).